Floatz logo

Rivaroxaban

Coronary Artery Disorder

Sheffield Teaching Hospitals NHS Foundation TrustSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Coronary Artery Disorder cohort.

Asset / SponsorPhaseRating
Aspirin
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
Ezetimibe
Canadian Collaborative Research Network
Phase 4BBB
SIMVASTATIN
University of Washington
Phase 4BBB
Ranolazine
OBS Pakistan
Phase 4BBB
Itavastatin
Yokohama City University Medical Center
Phase 4BBB

View all 48 →

Same molecule, other indications

Rivaroxaban is also rated in:

atrial fibrillationActive
BBB
Indicative · Phase 4
79 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
thrombotic diseaseActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →